###begin article-title 0
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 96 100 <span type="species:ncbi:10090">Mice</span>
Idd Loci Synergize to Prolong Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice
###end article-title 0
###begin p 1
###xml 39 64 39 64 <email xmlns:xlink="http://www.w3.org/1999/xlink">dale.greiner@umassmed.edu</email>
Corresponding author: Dale L. Greiner, dale.greiner@umassmed.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
OBJECTIVE-NOD mice model human type 1 diabetes and are used to investigate tolerance induction protocols for islet transplantation in a setting of autoimmunity. However, costimulation blockade-based tolerance protocols have failed in prolonging islet allograft survival in NOD mice.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 212 215 212 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS-To investigate the underlying mechanisms, we studied the ability of costimulation blockade to prolong islet allograft survival in congenic NOD mice bearing insulin-dependent diabetes (Idd) loci that reduce the frequency of diabetes.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 103 112 103 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd5</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 255 264 255 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd5</italic>
###xml 358 361 358 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 583 585 583 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 727 731 727 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
###xml 732 736 <span type="species:ncbi:10090">mice</span>
RESULTS-The frequency of diabetes is reduced in NOD.B6 Idd3 mice and is virtually absent in NOD.B6/B10 Idd3 Idd5 mice. Islet allograft survival in NOD.B6 Idd3 mice treated with costimulation blockade is prolonged compared with NOD mice, and in NOD.B6/B10 Idd3 Idd5, mice islet allograft survival is similar to that achieved in C57BL/6 mice. Conversely, some Idd loci were not beneficial for the induction of transplantation tolerance. Alloreactive CD8 T-cell depletion in (NOD x CBA)F1 mice treated with costimulation blockade was impaired compared with similarly treated (C57BL/6.H2g7 x CBA)F1 mice. Injection of exogenous interleukin (IL)-2 into NOD mice treated with costimulation prolonged islet allograft survival. NOD.B6 Idd3 mice treated with costimulation blockade deleted alloreactive CD8 T-cells and exhibited prolonged islet allograft survival.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il2</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 204 207 204 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
CONCLUSIONS-Il2 is the Idd3 diabetes susceptibility gene and can influence the outcome of T-cell deletion and islet allograft survival in mice treated with costimulation blockade. These data suggest that Idd loci can facilitate induction of transplantation tolerance by costimulation blockade and that IL-2/Idd3 is a critical component in this process.
###end p 6
###begin p 7
Published ahead of print at  on 4 November 2008.
###end p 7
###begin p 8
The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
###end p 8
###begin p 9
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 9
###begin p 10
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 367 370 367 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 592 595 592 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 717 721 717 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 729 730 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 731 732 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
The NOD mouse is a model of type 1-like autoimmune diabetes and is used to study costimulation blockade-based transplantation tolerance within the context of autoimmunity (1-4). However, costimulation blockade protocols fail in NOD mice. To investigate further the cellular and genetic control of costimulation blockade-induced transplantation tolerance, we used NOD Idd congenic mice that have small introgressed regions of genetic intervals derived from diabetes-resistant C57 stocks. These mice exhibit varying degrees of protection from autoantibodies, insulitis, and diabetes (5). Using Idd congenic NOD mice, we have observed that islet allograft survival is improved by the addition of the diabetes-protective Idd3 locus (6,7).
###end p 10
###begin p 11
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 998 1000 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
Idd3 modulates infiltration of autoreactive lymphocytes into the islets (8), and there is compelling evidence that Idd3 is the interleukin (IL)-2 gene (9). In vivo stimulated NOD T-cells produce twofold less IL-2 mRNA than cells from NOD congenic mice having protective alleles at Idd3 (9,10). Neutralizing antibodies to IL-2 lead to accelerated disease in NOD mice (11), and targeted genetic disruption of IL-2 accelerates type 1-like autoimmune diabetes (9). Treatment with exogenous IL-2 inhibits diabetes development in NOD mice and improves T regulatory (Treg) function (12). IL-2 is also known to have a nonredundant role in CD8 T-cell activation-induced cell death via the CD95 (Fas) pathway (13), is required for the development of self-tolerance (14), and is essential for the induction of allograft tolerance by costimulation blockade (15). However, IL-2 is a double-edged sword, since administration of IL-2 in vivo can either enhance or depress a cytotoxic T lymphocyte (CTL) response (16).
###end p 11
###begin p 12
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 383 392 383 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd5</italic>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
In this study, we show that costimulation blockade fails to delete alloreactive CD8 T-cells in NOD mice. Genetic replacement of IL-2 in NOD.B6 Idd3 mice enhances alloreactive CD8 T-cell deletion and improves islet allograft survival. Finally, we show that Idd3 synergizes with genes within the Idd5 interval, leading to permanent islet allograft survival in a majority of NOD.B6/B10 Idd3 Idd5 mice treated with costimulation blockade.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">k</sup>
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>k</sup></italic>
###xml 169 173 169 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">scid</sup>
###xml 164 173 164 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prkdc<sup>scid</sup></italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">scid</italic>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 242 245 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>b</sup></italic>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 359 363 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 406 410 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 496 512 496 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd10 Idd18</italic>
###xml 549 560 549 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 719 723 719 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 765 769 765 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 882 886 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 964 970 964 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 990 992 990 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 988 992 988 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 1004 1006 1004 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 1002 1006 1002 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 1138 1140 1138 1140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 1136 1140 1136 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 1328 1329 1328 1329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">k</sup>
###xml 1326 1329 1326 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>k</sup></italic>
###xml 1342 1343 1342 1343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1383 1384 1383 1384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1386 1388 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 934 939 <span type="species:ncbi:10090">mouse</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
###xml 1145 1149 <span type="species:ncbi:10090">mice</span>
###xml 1173 1177 <span type="species:ncbi:10090">mice</span>
###xml 1331 1335 <span type="species:ncbi:10090">mice</span>
C3H/He (H2k) mice were obtained from the National Cancer Institute (Frederick, MD), The Jackson Laboratory (Bar Harbor, ME), or Taconic Farms (Germantown, NY). NOD-Prkdcscid (NOD-scid) mice were obtained from The Jackson Laboratory. C57BL/6 (H2b), NOD/Mrk-TacfBR, NOD.B6 Idd3R450 (Taconic line 1098), NOD.CZECH Idd3 (Taconic line 1590), NOD.B6 Idd3R450 + B10 Idd5R444 (Taconic lines 1591 and 6109), NOD.B6 Idd3R450 + B10 Idd5R467 (Taconic line 1573), NOD.B10 Idd5R444 (Taconic line 1094), NOD.B6 Idd3 Idd10 Idd18R323 (Taconic line 1538), and NOD.B6 Idd10 Idd18(R2) (Taconic lines 1101 and 7754) were obtained from Taconic Farms. Because the experimental data using the NOD.B6 Idd3R450 (Taconic line 1098) and NOD.CZECH Idd3 (Taconic line 1590) congenic variants of Idd3 were comparable (9), these groups have been combined for presentation and are referred to in the text as NOD.B6 Idd3 mice. A schematic of the congenic intervals on mouse chromosomes is shown in Fig. 1. C57BL/6.NODc17 (H2g7, C57BL/6.H2g7) mice were developed by Edward Wakeland, University of Texas Southwestern Medical Center, Dallas, Texas (17). (KB5 CBA x C57BL/6.H2g7) F1 mice and (KB5 CBA x NOD) F1 mice were generated by a single intercross of the appropriate parental strains and were bred in our facility. The KB5 TCR transgene is expressed in CBA (H2k) mice by CD8+ T-cells and is specific for native H2-Kb (18).
###end p 14
###begin p 15
###xml 356 404 356 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Guide for the Care and Use of Laboratory Animals</italic>
Animals were certified to be free of infectious pathogens, housed in microisolator cages within a specific pathogen-free facility, and given autoclaved food and acidified water ad libitum. All animal use was in accordance with the guidelines of the Animal Care and Use Committee of the University of Massachusetts Medical School and recommendations in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council, National Academy of Sciences, 1996).
###end p 15
###begin title 16
Generation of KB5 synchimeras.
###end title 16
###begin p 17
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 199 201 199 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 295 298 295 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">137</sup>
###xml 420 421 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 464 466 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 462 466 462 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">Mice</span>
KB5 synchimeric mice were generated using a previously described procedure (18). Briefly, (CBA/J x NOD)F1 mice carrying a single copy of a B6-like allele of the IL-2 gene (19) and (CBA/J x C57BL/6.H2g7)F1 mice carrying two copies of a B6 or B6-like IL-2 gene were irradiated with 400 cGy from a 137Cs source (Gammacell 40; Atomic Energy of Canada, Ottawa, ON, Canada) and given a single intravenous injection of 0.5 x 106 (KB5 CBA x NOD)F1 or (KB5 CBA x C57BL/6.H2g7)F1 transgenic bone marrow cells, respectively. Mice were entered into experiments 8-12 weeks after bone marrow transplantation.
###end p 17
###begin title 18
Antibodies and flow cytometry.
###end title 18
###begin p 19
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
###xml 220 225 <span type="species:ncbi:10090">mouse</span>
###xml 360 363 <span type="species:ncbi:10116">rat</span>
###xml 412 417 <span type="species:ncbi:10090">mouse</span>
The KB5-specific clonotypic Desire (DES) antibody was the gift of Dr. John Iacomini (Harvard Medical School, Boston, MA). Fluorescein isothiocyanate-conjugated anti-mouse IgG2a (clone R19-15) and PerCept-conjugated anti-mouse CD8alpha monoclonal antibodies (mAbs) (clone 53-6.7) were obtained from BD PharMingen (San Diego, CA). Isotype control mAbs including rat PerCP-conjugated IgG2a kappa (clone R35-95) and mouse IgG2a kappa anti-TNP (clone G155-178) were purchased from BD PharMingen.
###end p 19
###begin p 20
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 699 700 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 319 324 <span type="species:ncbi:10090">mouse</span>
Two-color flow cytometry analyses of lymph node and spleen cells were performed (20). Briefly, cells were incubated with anti-FcgammaRIII/II mAb (clone 2.4G2) to eliminate nonspecific Fc binding. Cells were washed, incubated with anti-DES antibody, washed, and incubated with fluorescein isothiocyanate-conjugated anti-mouse IgG2a mAb plus a mixture of conjugated mAbs. Whole blood was processed using fluorescence-activated cell sorter lysing solution (Becton Dickinson, Sunnyvale, CA). Labeled cells were washed, fixed with 1% paraformaldehyde-PBS, and analyzed using a FACScan instrument (Becton Dickinson). Lymphoid cells were gated according to their light-scattering properties, and 30-50 x 103 events were acquired for each analysis.
###end p 20
###begin p 21
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
MR1 hamster anti-mouse CD154 mAb was produced as tissue culture supernatant and purified by affinity chromatography (National Cell Culture Center, Minneapolis, MN) (18). Contaminating endotoxin was uniformly <10 units/mg of mAb.
###end p 21
###begin title 22
Histology.
###end title 22
###begin p 23
Kidneys bearing islet grafts were fixed in Bouin's solution. Paraffin-embedded sections were prepared and stained with hematoxylin and eosin. Additional sections were stained for the presence of insulin and glucagon.
###end p 23
###begin title 24
Tolerance induction and allograft transplantation.
###end title 24
###begin p 25
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 578 579 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 728 729 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">Mice</span>
###xml 442 446 <span type="species:ncbi:10090">mice</span>
Diabetes was induced in 6- to 8-week-old male mice by a single intraperitoneal injection of streptozotocin (150 mg/kg) (6). Animals were tested for glycosuria (test strips, Glucosin; Bayer, Elkhart, IN) twice weekly. Diabetes was confirmed by documenting plasma glucose concentration >250 mg/dl (Accu-Chek Active, Roche Diagnostics, Indianapolis, IN.). Mice hyperglycemic for at least 1 week were used in the experiments. Chemically diabetic mice were treated with our standard costimulation blockade protocol consisting of a single C3H/He donor-specific transfusion (DST) of 107 spleen cells injected intravenously on day -7 and with anti-CD154 mAb (0.5 mg/dose) on days -7, -4, 0, and +4 relative to transplantation on day 0 (6).
###end p 25
###begin p 26
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
Islets isolated from C3H/He donors by collagenase digestion followed by density gradient separation were transplanted (20 islets/g body weight) into the renal subcapsular space of chemically diabetic recipients (21,22). Animals were tested for glycosuria twice weekly, and allograft rejection was defined as recurrent hyperglycemia (>250 mg/dl) on at least 2 consecutive days. Unilateral nephrectomy of the graft-bearing kidney was performed on all islet allograft recipients that were normoglycemic at the conclusion of an experiment to confirm allograft function.
###end p 26
###begin p 27
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
(KB5 CBA x NOD)F1 or (KB5 CBA x C57BL/6.H2g7)F1 synchimeric mice were treated with C57BL/6 DST and anti-CD154 mAb (18).
###end p 27
###begin title 28
Injection of IL-2 during costimulation blockade.
###end title 28
###begin p 29
###xml 157 158 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 162 163 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 12 18 <span type="species:ncbi:10090">murine</span>
Recombinant murine IL-2 (0.8 mug, R&D systems, Minneapolis, MN) was injected intraperitoneally on days -7, -6, -5, -4, and -3 relative to analysis of KB5 DES+ CD8+ T-cells or transplantation on day 0. Concurrently, costimulation blockade consisting of DST on day -7 and injections of anti-CD154 mAb on days -7, -4, 0, and +4 were performed relative to transplantation on day 0.
###end p 29
###begin title 30
In vivo cytotoxicity assay.
###end title 30
###begin p 31
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
The in vivo cytotoxicity assay was performed as previously described (23). Briefly, 6- to 8-week-old male NOD, C57BL/6, or NOD.B6 Idd3 mice were treated on day -7 with DST and on days -7 and -4 with anti-CD154 mAb relative to depletion of natural killer (NK) cells on day -8 by injection of 1 mg anti-CD122 mAb (24). On day 0 (the normal day of islet transplantation), carboxyfluorescein diacetate succinimidyl ester-labeled splenocytes were adoptively transferred intravenously into naive recipient mice or into the indicated recipient mice. Spleens from recipient mice were harvested 20 h later, and the survival of each transferred population was assessed by flow cytometry. Specific lysis was calculated as described (23).
###end p 31
###begin title 32
In vitro NK cell cytotoxicity assay.
###end title 32
###begin p 33
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 205 207 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">51</sup>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
The in vitro NK cell cytotoxicity assay was performed as previously described (25) using spleen cells from mice injected 24 h previously with 100 mug polyinosinic:polycytidylic (poly I:C) as effectors and 51Cr-labeled YAC-1 cells as targets. In some cohorts, NK cells were depleted by injection of 1 mg anti-CD122 mAb 1 day before poly I:C administration. Percent specific lysis was calculated as follows: % specific lysis = [(experimental lysis -spontaneous lysis)/(maximal lysis -spontaneous lysis)] x 100.
###end p 33
###begin title 34
Statistical analysis.
###end title 34
###begin p 35
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 402 403 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Median duration of allograft survival is presented. Graft survival among groups was compared using the method of Kaplan and Meier. The equality of allograft survival distributions for animals in different treatment groups was tested using the log rank statistic. P values <0.05 were considered statistically significant. Data are presented as the mean +/- 1 SD. Comparisons of two means used Student's t test with separate variance estimates. Comparisons of three or more means used one-way ANOVA and the least significant difference procedure for a posteriori contrasts.
###end p 35
###begin title 36
RESULTS
###end title 36
###begin title 37
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Islet allograft rejection in chemically diabetic male NOD mice is not due to islet autoimmunity.
###end title 37
###begin p 38
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 366 370 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">scid</italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
Islet allograft survival in chemically diabetic male NOD mice treated with our costimulation blockade protocol is relatively short (6). However, in those experiments, islet graft rejection could have resulted from islet autoimmunity or the failure to induce allograft tolerance. To investigate this, chemically diabetic NOD mice were transplanted with syngeneic NOD-scid islets. As reported previously (26), we observed through 150 days after islet transplantation that all mice (5/5) remained normoglycemic. Analysis of the islet-bearing kidney revealed an insulin-producing islet graft present at the time of necropsy with only a small amount of leukocytic infiltrate. These data suggest that islet allograft rejection in our model system results from failure to induce tolerance and not to the development of islet autoimmunity.
###end p 38
###begin title 39
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Islet allograft survival in NOD.B6 Idd10 Idd18 and NOD.B6 Idd3 Idd10 Idd18 congenic mice after treatment with DST and anti-CD154 mAb.
###end title 39
###begin p 40
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 190 193 190 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 251 257 251 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 297 300 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 418 429 418 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
Islet allograft survival is prolonged in NOD mice bearing the diabetes-resistant Idd3 congenic interval (6). However, Idd3 is only partially protective but, when combined with certain other Idd loci, almost completely protects NOD mice from diabetes (Fig. 1). We hypothesized that combinations of Idd loci that are strongly protective against diabetes would enhance islet allograft survival. NOD mice congenic for the Idd10 Idd18 intervals have reduced incidence of diabetes (27,28) and, when combined with Idd3, have a very low frequency of diabetes (8,27,29).
###end p 40
###begin p 41
###xml 32 33 32 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 288 289 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 282 289 282 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 523 524 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 517 524 517 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 562 573 562 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 679 685 679 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 707 718 707 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 768 772 768 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 850 854 850 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 880 881 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 886 887 886 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 874 887 874 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
###xml 864 868 <span type="species:ncbi:10090">mice</span>
Confirming our previous report (6), islet allograft survival in NOD mice treated with costimulation blockade is short (median survival time [MST] was 74 days), whereas permanent islet allograft survival (MST >240 days) is observed in the majority of similarly treated C57BL/6 mice (Fig. 2A). We also confirmed that NOD mice bearing the Idd3 congenic interval exhibit islet allograft survival that is prolonged (MST = 140 days, [6]) compared with NOD mice but significantly shorter than that achieved in C57BL/6 mice (Fig. 2B). Surprisingly, we observed that NOD Idd10 Idd18 congenic mice exhibited shorter islet allograft survival (MST = 63 days) than that achieved in NOD mice (Fig. 2). Combination of the Idd10 Idd18 genetic intervals with the beneficial effects of Idd3 did not alter islet allograft survival compared with that achieved in NOD.B6 Idd3 congenic mice (NS, Fig. 2A and B).
###end p 41
###begin title 42
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Protective Idd5 and Idd3 alleles synergize to prolong islet allograft survival in chemically diabetic NOD mice treated with DST and anti-CD154 mAb.
###end title 42
###begin p 43
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
We next studied the effects of Idd5 alone or in combination with Idd3. NOD mice bearing the Idd5 disease-resistant loci are partially protected from diabetes (30,31), and the addition of Idd3 protective alleles results in nearly complete disease suppression (31,32).
###end p 43
###begin p 44
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 177 178 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 171 178 171 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 270 277 270 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 317 328 317 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 398 401 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
NOD.B10 Idd5 congenic mice treated with DST and anti-CD154 did not exhibit prolonged islet allograft survival (MST = 96 days) compared with that achieved in NOD mice (NS, Fig. 2B) and was significantly shorter than that achieved in NOD.B6 Idd3 congenic mice (P < 0.005, Fig. 2B). These data, combined with the NOD.B6 Idd10 Idd18 results, demonstrate that enhancement of islet allograft survival by Idd loci does not strictly correlate with the extent to which they suppress diabetes.
###end p 44
###begin p 45
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 279 283 279 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 300 307 300 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 200 202 <span type="species:ncbi:10090">NS</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
Strikingly, NOD mice bearing the diabetes-protective Idd3 and Idd5 congenic intervals exhibited prolonged islet allograft survival (MST >250 days), which was similar to that achieved in C57BL/6 mice (NS) and significantly greater than that achieved in NOD (P < 0.005) or NOD.B10 Idd5 mice (P < 0.01, Fig. 2B). In long-term surviving islet allografts, we routinely observed minimal to no mononuclear infiltration.
###end p 45
###begin title 46
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Islet allograft survival in Idd3 congenic NOD mice bearing different Idd5 subregions treated with costimulation blockade.
###end title 46
###begin p 47
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.3</italic>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 422 428 422 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 444 450 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.3</italic>
###xml 462 468 462 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
The Idd5 interval congenic strain used in this study contains at least three diabetes-resistant loci: Idd5.1, Idd5.2, and Idd5.3 (30,31). To begin to identify the congenic Idd5 interval that synergizes with Idd3 to prolong islet allograft survival in NOD mice treated with costimulation blockade, we tested two newly developed NOD congenic lines that carry the B6-derived Idd3 congenic interval as well as the B10-derived Idd5.1 or Idd5.1 plus Idd5.3 intervals (Fig. 1).
###end p 47
###begin p 48
###xml 7 11 7 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 168 169 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 234 240 234 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 309 322 309 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1 Idd5.3</italic>
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 408 414 408 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 538 542 538 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 617 623 617 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 647 653 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 657 663 657 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.3</italic>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 230 232 <span type="species:ncbi:10090">NS</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 398 402 <span type="species:ncbi:10090">mice</span>
###xml 404 406 <span type="species:ncbi:10090">NS</span>
NOD.B6 Idd3 B10 Idd5.1 congenic mice treated with costimulation blockade exhibited islet allograft survival shorter (MST = 69 days) than that achieved in C57BL/6 mice (P < 0.0001) and not different from that achieved in NOD mice (NS, Fig. 3). Islet allograft survival was also not enhanced in NOD.B6 Idd3 B10 Idd5.1 Idd5.3 mice (MST = 13 days) over that achieved in NOD.B6 Idd3 B10 Idd5.1 congenic mice (NS, Fig. 3). These data suggest that expression of Idd5.2 encoding a nonfunctional protein is important for the beneficial effects of Idd5 in conjunction with Idd3 and that all three subregions are needed-or that Idd5.2 alone or in combo with Idd5.1 or Idd5.3 is beneficial. Interestingly, we observed that a proportion of animals maintained long-term graft function.
###end p 48
###begin title 49
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Failure of costimulation blockade treatment to delete alloreactive CD8+ T-cells in (NOD x KB5)F1 synchimeric mice is reversed by IL-2.
###end title 49
###begin p 50
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
Idd3-mediated diabetes susceptibility in NOD mice is caused by an IL-2 allele that is transcribed at lower levels than variants contributing to disease resistance (9) and is important for tolerance induction (33). Therefore, we hypothesized that a deficiency in IL-2 production in NOD mice impairs host alloreactive CD8+ T-cell deletion.
###end p 50
###begin p 51
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 181 183 181 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 517 522 <span type="species:ncbi:10090">mouse</span>
To test this hypothesis, we modified our synchimera model system based on KB5 TCR transgenic alloreactive CD8+ T-cells (18). KB5 CBA mice were mated with NOD mice or with C57BL/6.H2g7 mice bearing the NOD major histocompatibility complex and were used to generate synchimeric mice (18). Synchimeric mice were treated with C57BL/6 DST and anti-CD154, and the circulating levels of KB5 transgenic alloreactive CD8+ T-cells were analyzed on day 0. Two groups of synchimeric mice were also given five daily injections of mouse rIL-2 beginning on the day of DST.
###end p 51
###begin p 52
###xml 21 23 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">.H2<sup>g7</sup></italic>
###xml 131 132 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 154 160 152 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 217 219 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 214 219 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">.H2<sup>g7</sup></italic>
###xml 419 420 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 563 565 555 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 560 565 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">.H2<sup>g7</sup></italic>
###xml 575 581 567 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 569 573 <span type="species:ncbi:10090">mice</span>
(KB5 CBA x C57BL/6.H2g7)F1 synchimeric mice treated with costimulation blockade exhibited marked deletion of their alloreactive CD8+ T-cells (63 +/- 30%, Fig. 4). Similar results were seen in the (KB5 CBA x C57BL/6.H2g7)F1 synchimeric mice that received exogenous IL-2 in addition to the DST and anti-CD154 (70 +/- 6%). In contrast, (KB5 CBA x NOD)F1 mice exhibited significantly less deletion of their alloreactive CD8+ T-cell population (34 +/- 24%), which was restored by IL-2 treatment (63 +/- 21%) to a level similar to that observed in (KB5 CBA x C57BL/6.H2g7)F1 mice (Fig. 4).
###end p 52
###begin title 53
###xml 46 50 <span type="species:ncbi:10090">mice</span>
IL-2 improves islet allograft survival in NOD mice treated with costimulation blockade.
###end title 53
###begin p 54
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
We next hypothesized that increased deletion of alloreactive CD8+ T-cells in (KB5 CBA x NOD)F1 mice treated with costimulation blockade plus IL-2 would lead to a difference in islet allograft survival. To test this, chemically diabetic NOD mice were treated with costimulation blockade and transplanted with C3H/He islets with or without peri-transplant injection of IL-2.
###end p 54
###begin p 55
###xml 13 14 13 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 116 122 116 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 337 343 337 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
As expected (6), islet allograft survival in NOD mice treated with costimulation blockade was short (MST = 46 days, Fig. 5). In contrast, NOD mice treated with costimulation blockade and IL-2 exhibited slightly but significantly prolonged islet allograft survival (MST = 83 days), although all islet allografts were eventually rejected (Fig. 5).
###end p 55
###begin title 56
###xml 21 25 <span type="species:ncbi:10090">mice</span>
NOD.B6 Idd3 congenic mice exhibit a restored ability to delete alloreactive CD8 T-cells after costimulation blockade.
###end title 56
###begin p 57
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 71 77 71 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 196 202 196 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
Having observed that the Idd3 locus improved islet allograft survival (Fig. 5) and that exogenous administration of IL-2 improved alloreactive CD8 T-cell deletion in our synchimeric model system (Fig. 4), we next tested directly our hypothesis that restoration of a normal IL-2 gene by the Idd3 locus in NOD mice would restore the ability of costimulation blockade to delete alloreactive CD8 T-cells. To directly identify alloreactive CD8 T-cell function in NOD.B6 Idd3 mice, we used an in vivo cytotoxicity assay (23). In NK cell-depleted mice, all in vivo cytotoxic activity is due to alloreactive CD8 T-cells (34).
###end p 57
###begin p 58
###xml 20 22 20 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 110 117 110 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 299 300 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 293 300 293 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 325 329 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 465 472 465 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 605 612 605 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
We first confirmed (24) that the anti-CD122 antibody would delete all NK cell cytotoxic activity in NOD mice (Fig. 6A). As expected, NK-depleted C57BL/6 mice treated with costimulation blockade exhibited low in vivo cytotoxicity, whereas alloreactive CD8 T-cell activity in NOD mice was high (Fig. 6B). In NK-depleted NOD.B6 Idd3 mice, in vivo cytotoxicity was significantly lower than that observed in NOD mice and was comparable to that observed in C57BL/6 mice (Fig. 6B). In all three strains, priming NK cell-depleted mice with a DST alone induced strong in vivo alloreactive CD8 T-cell cytotoxicity (Fig. 6B).
###end p 58
###begin title 59
DISCUSSION
###end title 59
###begin p 60
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 157 158 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 199 202 199 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 468 472 468 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
We have confirmed in this article that islet allograft survival in NOD.B6 Idd3 mice treated with costimulation blockade is prolonged compared with NOD mice (1). We now document that some but not all Idd resistance loci synergize with Idd3 to enhance islet allograft survival. We further show that a major tolerance defect in NOD mice is the resistance of alloreactive CD8 T-cells to deletion by costimulation blockade, a defect that can be reversed by addition of the Idd3 gene or by administration of exogenous IL-2.
###end p 60
###begin p 61
###xml 33 44 33 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 136 146 136 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd10</italic>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd18</italic>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 249 260 249 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 277 293 277 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd10 Idd18</italic>
###xml 449 460 449 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 560 564 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
Disease-resistant alleles at the Idd10 Idd18 region provide moderate protection against diabetes (45-55%) (27,28,35), and together, the Idd3 Idd10 and Idd18 protective alleles confer almost complete resistance (8,27,29). We hypothesized that NOD.B6 Idd10 Idd18 mice and NOD.B6 Idd3 Idd10 Idd18 mice would demonstrate a stepwise improvement in costimulation blockade-induced islet allograft survival. Surprisingly, islet allograft survival in NOD.B6 Idd10 Idd18 mice was not increased over that achieved in NOD mice and did not increase over that achieved with Idd3 alone.
###end p 61
###begin p 62
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10</italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd18</italic>
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptpn22</italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 452 458 452 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptpn22</italic>
###xml 815 826 815 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 236 241 <span type="species:ncbi:9606">human</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
Genes located within the Idd10 and Idd18 intervals include Ptpn22, which is orthologous to PTPN22, a human gene that is associated with the development of diabetes and other autoimmune diseases (28,36). The disease-associated allele of human PTPN22 is a gain-of-function variant that in vitro suppresses TCR signaling in response to TCR/CD28 ligation to a greater extent than the more common allele (37). The functional outcome of TCR signaling in the PTPN22 gain-of-function variant reduces expression of IL-2. Studies that altered the allelic status of the Ptpn22 region in NOD congenic mice have demonstrated that the B6-derived interval confers susceptibility to type 1-like autoimmune diabetes (L.S.W., L.B.P., unpublished data), therefore providing a potential explanation for the inability of the B6-derived Idd10 Idd18 region to increase islet allograft survival.
###end p 62
###begin p 63
###xml 50 66 50 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd10 Idd18</italic>
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 399 408 399 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd5</italic>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
Given the surprising results seen with the NOD.B6 Idd3 Idd10 Idd18 islet allograft studies, we next determined whether a synergistic effect could be found between Idd3 and Idd5. NOD.B10 Idd5 mice have a lower frequency of diabetes than NOD mice, and when combined with resistance alleles at Idd3, the frequency of spontaneous diabetes is <2% (30,32). Importantly, islet allograft survival in NOD.B6 Idd3 Idd5 mice was increased to levels achieved in C57BL/6 mice.
###end p 63
###begin p 64
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.3</italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ctla4</italic>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 409 416 409 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Slc11a1</italic>
###xml 436 442 436 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nramp1</italic>
###xml 471 477 471 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 531 537 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nramp1</italic>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 592 605 592 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2/Nramp1</italic>
###xml 669 673 669 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 678 682 678 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 714 720 714 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 801 805 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 850 862 850 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1/Ctla4</italic>
###xml 867 871 867 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 947 951 947 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1062 1066 1062 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 1071 1075 1071 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 1246 1252 1246 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 1307 1311 1307 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 1425 1436 1425 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3/Idd5.3</italic>
###xml 1438 1449 1438 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3/Idd5.2</italic>
###xml 1455 1473 1455 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3/Idd5.2/Idd5.3</italic>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
The Idd5 congenic strain used in our study contains at least three diabetes resistance genes, termed Idd5.1, Idd5.2, and Idd5.3 (30). The Idd5.1 gene is most likely a variant of Ctla4, with the diabetes-prone NOD allele producing less of the ligand-independent CTLA-4 (liCTLA-4) molecule than the resistant B10 allele (38). CTLA-4 is critical for the induction of tolerance using costimulation blockade (39). Slc11a1 (formerly known as Nramp1) is likely to be the causal Idd5.2 gene (40). Interestingly, the B10 diabetes-resistant Nramp1 allele encodes a nonfunctional protein (41). However, Idd5.2/Nramp1 is not required for the decreased diabetes frequency in NOD.B6 Idd3 B10 Idd5 mice, although the B10-derived Idd5.2 region is required to maintain the reduced insulitis present in NOD.B6 Idd3 B10 Idd5 mice (31). In addition, the non-NOD-derived Idd5.1/Ctla4 and Idd3 resistance alleles did not increase protection from diabetes compared with Idd3 alone (31). These results are consistent with our islet allograft survival data. The synergy observed between Idd5 and Idd3 that results in nearly complete protection from diabetes and insulitis and increases islet allograft survival to a C57BL/6-like frequency is dependent on the B10-derived Idd5.2 region, either alone or in combination with the other Idd5 loci. To extend this observation, additional congenic strain combinations would have to be developed and tested: Idd3/Idd5.3, Idd3/Idd5.2, and Idd3/Idd5.2/Idd5.3.
###end p 64
###begin p 65
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
Idd3, which is partially protective of diabetes, significantly improves islet allograft survival in the NOD mouse, with the strongest effect seen in the NOD.B6 Idd3 B10 Idd5 congenic strain. The Idd3 effect likely results from differential expression of IL-2 that modulates CD4+CD25+ Treg cell function in NOD mice (9). IL-2 is also required for the development of self-tolerance and for costimulation blockade-induced allograft tolerance (10,15).
###end p 65
###begin p 66
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 278 280 278 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 275 280 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">.H2<sup>g7</sup></italic>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 531 532 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 653 654 653 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 605 609 <span type="species:ncbi:10090">mice</span>
Based on the NOD.B6 Idd3 congenic data, we hypothesized that the inability to induce tolerance in NOD mice is due to a failure to efficiently delete host alloreactive CD8+ T-cells and that injection of exogenous IL-2 would correct this defect. As expected, (KB5 CBA x C57BL/6.H2g7)F1 synchimeric mice treated with costimulation blockade showed a marked deletion of alloreactive CD8+ T-cells compared with (KB5 CBA x NOD)F1 synchimeric mice. When (KB5 CBA x NOD)F1 synchimeric mice were treated with exogenous IL-2, alloreactive CD8+ T-cell deletion was significantly improved. These data suggest that NOD mice fail to efficiently delete alloreactive CD8+ T-cells because of insufficient IL-2 production.
###end p 66
###begin p 67
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 761 765 761 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 912 913 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1034 1035 1034 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1061 1064 1061 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il2</italic>
###xml 1065 1069 1065 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 1149 1153 1149 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 1184 1185 1184 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 442 446 <span type="species:ncbi:10090">mice</span>
###xml 634 638 <span type="species:ncbi:10090">mice</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
###xml 1178 1182 <span type="species:ncbi:10090">mice</span>
To extend this finding, we observed that islet allograft survival in NOD mice treated with costimulation blockade plus IL-2 was slightly longer than in those receiving costimulation blockade alone, likely through enhancement of alloreactive CD8 T-cell apoptosis (16). This interpretation has previously been proposed based on the observation that coadministration of rapamycin plus IL-2 prevents spontaneous and recurrent autoimmunity in NOD mice through the ability of rapamycin to inhibit IL-2 T-cell proliferation but not IL-2-induced apoptosis (42). The fact that graft survival isn't as prolonged as that achieved in NOD.B6 Idd3 mice may be due to the transient administration of IL-2 and its short half-life, whereas the increased IL-2 achieved in NOD.B6 Idd3 mice is present throughout the animal's life. Alternatively, we had previously documented in CD8-deficient NOD and (NOD x C57BL/6)F1 mice that CD8+ T-cells are not solely responsible for the failure to induce prolonged allograft survival after costimulation blockade (7), implicating a role for Il2/Idd3 in other transplantation tolerance pathways, consistent with the known role of Idd3 in Treg function in NOD mice (9).
###end p 67
###begin p 68
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 315 316 315 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
These data suggest that impaired production of IL-2 in NOD mice is a barrier to costimulation blockade-induced tolerance. IL-2 is indispensable for supporting the in vivo growth, survival, and function of naturally occurring Tregs (11,43-46), and because of their corrected Idd3 haplotype, NOD.B6 Idd3 mice have CD4+CD25+ Tregs with enhanced regulatory activity (9).
###end p 68
###begin p 69
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 279 282 279 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il2</italic>
###xml 351 355 351 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 654 660 <span type="species:ncbi:9606">humans</span>
In summary, we have shown that the resistance to costimulation blockade-induced tolerance to islet allografts in NOD mice is in part due to the failure to efficiently delete alloreactive CD8 T-cells. Genetically, this can be overcome by the introgression of a normal Idd3 (i.e., Il2) gene that synergizes with one or more protective subregions within Idd5 to promote allograft tolerance. Speculatively, we propose that the B6 allele of Idd3 might also contribute to the apoptosis of islet-specific CD8 cells in spontaneous diabetes. Because SNP polymorphisms in the IL-2 receptor have been associated with a genetic predisposition for type 1 diabetes in humans (47), these data suggest that regulation of IL-2 may be important not only for diabetes but also for islet transplantation in type 1 diabetic individuals.
###end p 69
###begin p 70
This study was supported in part by grants AR35506 and AI42669, an institutional Diabetes Endocrinology Research Center (DERC) grant (DK52530) from the National Institutes of Health, grant DK53006 from the National Institutes of Health, and a grant to L.D.S. from the Juvenile Diabetes Research Foundation (JDRF). T.P. was supported by a fellowship grant from JDRF. L.S.W. was supported by a joint grant from the JDRF and the Wellcome Trust. D.V.S. was supported by grants DK46266 and DK51090 from the National Institutes of Health, as well as by grants from the JDRF. L.D.S. was supported by JDRF Grant 1-2004-548.
###end p 70
###begin p 71
###xml 33 37 <span type="species:ncbi:10090">mice</span>
The availability of NOD congenic mice through the Taconic Farms Emerging Models Program has been supported by grants from the Merck Genome Research Institute, the National Institute of Allergy and Infectious Diseases, and the JDRF. No other potential conflicts of interest relevant to this article were reported.
###end p 71
###begin p 72
We thank Linda Paquin, Cindy Bell, Linda Leehy, Dan Rainbow, and Jean Leif for technical assistance.
###end p 72
###begin title 73
REFERENCES
###end title 73
###begin p 74
###xml 224 227 224 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 326 331 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10</italic>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd18</italic>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.1</italic>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.2</italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 437 443 437 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5.3</italic>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
Schematic representation of candidate gene interval and chromosomal location. The filled bars represent B10-derived or B6-derived congenic segments on chromosomes 1 and 3, respectively. The arrows represent the size of each Idd interval as previously defined using additional congenic strains of mice: Idd3 (650 kb) (ref. 9), Idd10 (950 kb) (ref. 48), Idd18 (4.0 Mb) (ref. 29), Idd5.1 (2.1 Mb) (ref. 30), Idd5.2 (1.52 Mb) (ref. 30), and Idd5.3 (3.6 Mb) (ref. 31). The "diabetes" column indicates the percentage of females developing diabetes by 7 months of age. Where a range is indicated, this summarizes the results of a number of frequency studies performed over many years.
###end p 74
###begin p 75
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 563 564 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 566 577 566 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd10 Idd18</italic>
###xml 582 598 582 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd10 Idd18</italic>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 621 625 621 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd5</italic>
###xml 633 646 633 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and Idd3/Idd5</italic>
###xml 724 725 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 743 744 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
###xml 660 664 <span type="species:ncbi:10090">mice</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
Life table analysis of islet allograft survival in chemically diabetic congenic NOD mice. The 6- to 8-week-old male mice were treated with a DST plus anti-CD154 mAb. DST (107 C3H/He spleen cells) was given on day -7, and anti-CD154 mAb (0.5 mg/dose) was given on days -7, -4, 0, and +4 relative to transplantation with C3H/He islets on day 0. Vertical bars indicate mice removed from the study with intact grafts or alive with intact grafts at the conclusion of the period of observation. Comparative P values of islet allograft survival in the groups are shown. A: Idd10 Idd18 and Idd3 Idd10 Idd18 congenic NOD mice. B: Idd3, Idd5, and Idd3/Idd5 congenic NOD mice. Islet allograft survival in C57BL/6 and NOD mice shown in A is reproduced in B for ease of comparison with other strains.
###end p 75
###begin p 76
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 614 623 614 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3 Idd5</italic>
###xml 647 653 647 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 728 729 728 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 633 637 <span type="species:ncbi:10090">mice</span>
Life table analysis of islet allograft survival in chemically diabetic Idd3 congenic NOD mice bearing different Idd5 congenic intervals. Groups of 6- to 8-week-old chemically diabetic male mice were treated with a DST plus anti-CD154 mAb. A DST (107 C3H/He spleen cells) was given on day -7, and anti-CD154 mAb (0.5 mg/dose) was given on days -7, -4, 0, and +4 relative to transplantation with C3H/He islets on day 0. Vertical bars indicate mice removed from the study with intact grafts or alive with intact grafts at the conclusion of the period of observation. Islet allograft survival in C57BL/6, NOD, and NOD Idd3 Idd5 congenic mice shown in Fig. 2 is reproduced here for ease of comparison with other strains. Comparative P values of islet allograft survival in the groups are shown.
###end p 76
###begin p 77
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g7</sup>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2<sup>g7</sup></italic>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 326 353 326 353 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 355 356 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Scatter plot of alloreactive CD8+ T-cell deletion in synchimeric mice. (KB5 CBA x C57BL/6.H2g7)F1 mice and (KB5 CBA x NOD)F1 synchimeric mice were treated with a C57BL/6 DST on day -7 and anti-CD154 mAb on days -7 and -4 relative to analysis of their circulating levels of KB5 transgenic CD8+ T-cells on day 0 as described in research design and methods. P values are indicated by horizontal bars.
###end p 77
###begin p 78
###xml 481 482 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 344 350 <span type="species:ncbi:10090">murine</span>
Life table analysis of islet allograft survival in NOD mice treated with IL-2. Groups of 6- to 8-week-old chemically diabetic NOD mice were treated with a C3H/He DST on day -7 and anti-CD154 mAb (0.5 mg/dose) on days -7, -4, 0, and +4 relative to transplantation with C3H/He islets on day 0. One group of mice also received 0.8 mug recombinant murine IL-2 (R&D systems, Minneapolis, MN) intraperitoneally on days -7, -6, -5, -4, and -3 relative to islet transplantation on day 0. *P < 0.05 vs. NOD.
###end p 78
###begin p 79
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 454 456 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 459 460 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 487 491 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 655 682 651 678 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 825 829 803 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 831 832 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 859 860 837 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 887 891 865 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idd3</italic>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
###xml 893 895 <span type="species:ncbi:10090">NS</span>
In vivo cytotoxicity activity of alloreactive CD8 T-cells in mice treated with costimulation blockade. A: NOD and C57BL/6 male mice 6-8 weeks of age were untreated or injected with 1.0 mg anti-CD122 mAb (clone TMbeta1). Twenty-four hours later, all groups were injected with 100 mug poly I:C, and 20 h later, spleen cells were recovered for analyses of in vitro NK cell cytotoxicity activity on the NK-sensitive cell line YAC-1, as previously described (25). B: NOD, C57BL/6, and NOD.B6 Idd3 mice were treated with costimulation blockade, depleted of NK cells and injected with CFSE-labeled spleen cells for an in vivo cytotoxicity assay, as described in research design and methods. o, DST; black triangle down, DST + anti-CD154. The number of mice tested in each group is indicated below each strain tested. NOD vs. NOD.B6 Idd3, P < 0.005; C57BL/6 vs. NOD, P < 0.01 C57BL/6 vs. NOD.B6 Idd3, NS.
###end p 79

